GCP
ANVS icon

GSA Capital Partners’s Annovis Bio ANVS Stock Holding History

GSA Capital Partners’s Portfolio ANVS Stock Details ANVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$101K Buy
+45,423
New +$125K 0.01% 1562

Other funds holding ANVS

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

GSA Capital Partners's ANVS Position: Q1 2026 in Review

GSA Capital Partners opened a new position in Annovis Bio (ANVS) in Q1 2026: 45,423 shares worth $101K. The stake represents 0.01% of the portfolio and ranks #1562 among its holdings.

56 funds tracked by Wall St. Rank hold ANVS as of Q1 2026.

  • GSA Capital Partners held 45,423 shares of Annovis Bio worth $101K as of Q1 2026.
  • Annovis Bio was a new GSA Capital Partners position in Q1 2026.
  • Annovis Bio made up 0.01% of GSA Capital Partners's portfolio in Q1 2026, its #1562 holding.
  • 56 funds tracked by Wall St. Rank held Annovis Bio as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.